Univariable analysis (based on the questionnaire answers) of the variables potentially associated with MRSA carriage and human-animal transmission.

<p>The ones that were significantly different between cases and controls are highlighted. “Don't know” or “missing” answers were excluded from the analysis. Legend: FM = family member; HCW = health care worker; AB = antibiotic.</p

PFGE comparison of human and animal MRSA pairs.

<p>PFGE comparison of human and animal MRSA pairs.</p

Summary of the classification of the MRSA isolates, using <i>spa</i> typing.

<p>Summary of the classification of the MRSA isolates, using <i>spa</i> typing.</p

Baseline characteristics of 473 patients with <i>S. aureus</i> complicated skin and skin structure infections (cSSSI) stratified by methicillin-resistance and <i>pvl</i> gene status of the infecting pathogen.

*<p> = P-Value from generalized 2-sided Fishers Exact Test. Calculated using 7×2 table (^∧), 4×2 table (§) and 3×2 table (±).</p>**<p> = P-Value from 2-sided T-test.</p>***<p> = P-value from Wilcoxon Rank Sum test.</p><p>1 = Subjects with missing data were not included in these summaries.</p

Clinical outcome of cure for 473 patients with methicillin-resistant and methicillin-susceptible <i>S. aureus</i> complicated skin and skin structure infections by <i>pvl</i> gene status, stratified by infection severity, diabetes, patient age, and study medication.

*<p> = P-Value from generalized 2-sided Fishers Exact Test.</p><p>Missing categories are not in the analyses.</p

Clinical outcome of cure for 266 patients with <i>pvl</i> positive <i>S. aureus</i> complicated skin and skin structure infections by pulsed-field gel type, stratified by infection severity, diabetes, patient age, methicillin-susceptibility and study medication.

*<p> = P-Value from generalized 2-sided Fishers Exact Test.</p>**<p>Receipt of a surgical procedure ≤48 hours post enrolment.</p><p>Missing categories are not in the analyses.</p

Single Nucleotide Polymorphisms (SNPs) in fibronectin binding protein B (<i>fnbB)</i> in <i>fnbB-</i>containing isolates.

<p>*When false discovery rate control is applied, this raw p-value no longer maintains statistical significance (p = 1.00).</p><p>No SNP was associated with the prosthetic joint infected (PJI) or uninfected (PJU) isolates in the derivation cohort, external validation cohort, or late <i>S</i>. <i>aureus</i> bacteremia (SAB) group. Late SAB was defined as SAB occurring >1 year after placement or manipulation of prostheses.</p

Demographic and clinical characteristics of patients in the derivation cohort with <i>S</i>. <i>aureus</i> bacteremia and infected or uninfected prostheses.

<p>*Late infection is defined as bloodstream infection occurring >1 year after the prostheses was implanted or surgically manipulated.</p><p>Demographic and clinical characteristics of patients in the derivation cohort with <i>S</i>. <i>aureus</i> bacteremia and infected or uninfected prostheses.</p

Comparison of the biofilm-forming capacity of <i>S</i>. <i>aureus</i> isolates from prosthetic joint infection (PJI) and uninfected prosthetic joint (PJU) groups.

<p>Values were calculated as percentage capacity to form biofilms relative to <i>S</i>. <i>aureus</i> control strain UAMS-1. Box ends represent the 25^th and 75^th percentiles, and whisker ends represent the minimum and maximum. There was no difference in biofilm-forming capacity between isolates in the PJI and PJU groups.</p

Comparison of the fibronectin binding capacity of <i>S</i>. <i>aureus</i> isolates from prosthetic joint infection (PJI) and uninfected prosthetic joint (PJU) groups.

<p>Values were calculated as percentage capacity to bind fibronectin relative to <i>S</i>. <i>aureus</i> control strain 8325–4. Box ends represent the 25^th and 75^th percentiles, and whisker ends represent the minimum and maximum. There was no difference in fibronectin binding capacity between isolates in the PJI and PJU groups.</p